Showing 6911-6920 of 18626 results for "".
Multidisciplinary Team Collaboration in the New Era of Hemophilia Treatment
https://reachmd.com/programs/cme/multidisciplinary-team-collaboration-in-the-new-era-of-hemophilia-treatment/35554/Don’t miss this opportunity to learn the latest in new and emerging hemophilia therapies and optimize your patient care strategies.MOA: CDH6-Targeted Antibody-Drug Conjugates
https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerPulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
https://reachmd.com/programs/cme/pulmonary-hypertension-getting-the-right-diagnosis-and-knowing-when-to-refer/36094/Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to ReferAn Overview of Current and Emerging Treatment Options for Hemophilia A & B
https://reachmd.com/programs/cme/an-overview-of-current-and-emerging-treatment-options-for-hemophilia-a-b/35546/Don’t miss this opportunity to learn the latest in new and emerging hemophilia therapies and optimize your patient care strategies.Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-clinical-and-laboratory-criteria-for-diagnosis-and-optimal-treatment-selection/29533/Navigating the diagnostic and treatment complexity of generalized myasthenia gravis is challenging. These clinical cases offer you options.TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/Are you as excited as we are to see how TROP2-targeted antibody-drug conjugates can help our patients?Postpartum Depression: A Common Yet Overlooked Condition
https://reachmd.com/programs/medical-industry-feature/postpartum-depression-overlooked-condition/29760/Postpartum depression (PPD) symptoms are reported by about 13 percent, or roughly one in eight women, after giving birth.1 Despite being one of the most common medical conditions associated with pregnancy,2 women suffering from PPD often go undiagnosed.2,3 Tune in to hear Dr. Sarah Oreck and Dr. BroADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
https://reachmd.com/programs/cme/adcs-across-the-spectrum-of-her2-expression-in-metastatic-breast-cancer/32202/Dr. Reshma Mahtani presents patient case challenges highlighting the use of antibody-drug conjugates in HER2-expressing metastatic breast cancer.From Risk to Results: Cases in ASCVD Prevention and Treatment
https://reachmd.com/programs/cme/from-risk-to-results-cases-in-ascvd-prevention-and-treatment/29823/Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcDuchenne Muscular Dystrophy: Differentiating Advances in Treatment
https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/While glucocorticoids are the current SOC for DMD, long-term exposure comes with debilitating side effects. A safer and more effective option is emerging.